The findings add to the existing literature, confirming the promise of AAV2-TGM1 as a platform for gene therapy of cutaneous monogenic diseases with low risk of systemic toxicity, at appropriate doses [32]. The gene discussed is TGM1; the disease is glycogen storage disease VI.